RecruitingNCT07566793

Validation of Effectiveness on NaturalCycles Users

A Prospective Observational Study on the Contraceptive Effectiveness of the Natural Cycles Application (The VENUS Study)


Sponsor

Natural Cycles

Enrollment

2,000 participants

Start Date

Apr 28, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to measure the effectiveness of the Natural Cycles digital birth control application at preventing pregnancy in sexually active women aged 18 to 35 with no known history of infertility. The main questions it aims to answer are: * What is the pregnancy rate of the application over one year, for all users? * What is the pregnancy rate of the application over one year, for users who follow the application's instructions perfectly? Participants will: * Use the Natural Cycles application for birth control for up to one year. * Log information about daily sexual activity in the app. * Complete a questionnaire at the beginning and end of their participation. * Perform urine pregnancy tests (provided by mail) upon entry to the study, at the start of every cycle during the study, and upon exit from the study.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 35 Years

Inclusion Criteria7

  • Wants to avoid pregnancy for 13 cycles.
  • Is willing to rely solely on Natural Cycles as their sole contraception method for 13 cycles.
  • Is not currently using permanent contraceptive methods, such as sterilization (of either the user or their partner), or hormonal methods, such as the hormonal contraceptive implant or IUD.
  • Has an intact uterus, both ovaries and both fallopian tubes to the best of their knowledge.
  • Has an average cycle length between 21 and 35 days. The user anticipates heterosexual intercourse at least once a month in the next year.
  • Is willing to enter data on a daily basis and perform pregnancy tests as requested by protocol.
  • Is willing to complete a satisfaction survey at the end of her study participation.

Exclusion Criteria9

  • Has EU-citizenship
  • Has had a Depo-Provera injection in the last 10 months or has had less than three consecutive, spontaneous menstrual cycles since their last injection.
  • Has had less than three consecutive, spontaneous menstrual cycles after removing a hormonal implant.
  • Has had less than three consecutive, spontaneous menstrual cycles after the end of a pregnancy.
  • Has had less than three consecutive, spontaneous menstrual cycles since she last breastfed.
  • Has (or partner has) known fertility issues, such as infertility and sterilization, or have been advised by a healthcare professional that they may have difficulty conceiving for any reason.
  • Has a medical condition possibly impacting fertility, i.e. endometriosis, a history of Pelvic Inflammatory Disease (PID), significant uterine fibroids or adenomyosis, or another diagnosed medical condition that they have been told affects fertility.
  • Is regularly taking one of the following prescribed pharmaceutical medications known to be teratogenic (i.e., a medication that can cause birth defects):
  • Isotretinoin (like Accutane, Absorica, Claravis, or Myorisan) for severe acne Valproic acid or divalproex sodium (like Depakote, Depakene, or Topamax) for seizures (epilepsy), migraines, or bipolar disorder Methotrexate (Trexall, Rheumatrex) or leflunomide (Arava) for autoimmune conditions ACE Inhibitors (like Lisinopril, Enalapril) or Angiotensin II Receptor Blockers (ARBs) (like Losartan, Valsartan) for high blood pressure or heart conditions Warfarin (Coumadin, Jantoven) for blood clot prevention

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALLog daily intercourse information

For the duration of their participation in the study, participants will use the contraceptive app as usual but will be prompted to diligently log daily intercourse information and to regularly test for pregnancy. Upon exiting the study for any reason, all participants will complete a urine pregnancy test and an online Exit Questionnaire.

DEVICENatural Cycles application

Users will receive daily fertility status from Natural Cycles application


Locations(1)

Natural Cycles USA Corp

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07566793


Related Trials